Loading
A phase 3 trial of Pegylated liposomal doxorubicin, Paclitaxel / nab-paclitaxel, Letrozole in ovarian cancer, run by Verastem, Inc., now recruiting.
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer is a phase 3 interventional study registered as NCT06072781 by Verastem, Inc., with 270 participants planned, started 2024-03-18 and due to reach its primary completion in 2028-10-15. Interventions recorded: avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole. Conditions listed: Low Grade Serous Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Verastem Oncology, Low-grade serous ovarian cancer, Ovarian cancer.
Shares Pegylated liposomal doxorubicin, Paclitaxel / nab-paclitaxel, Ovarian cancer.
Shares Pegylated liposomal doxorubicin, Paclitaxel / nab-paclitaxel, Ovarian cancer.
Shares Pegylated liposomal doxorubicin, Paclitaxel / nab-paclitaxel, Ovarian cancer.
Shares Pegylated liposomal doxorubicin, Paclitaxel / nab-paclitaxel, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/